Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BioAtla, Inc. (BCAB : NSDQ)
 
 • Company Description   
BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO.

Number of Employees: 61

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.39 Daily Weekly Monthly
20 Day Moving Average: 475,708 shares
Shares Outstanding: 58.42 (millions)
Market Capitalization: $22.58 (millions)
Beta: 0.91
52 Week High: $2.53
52 Week Low: $0.24
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.74% -13.12%
12 Week 19.40% 0.43%
Year To Date -34.61% -38.76%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11085 TORREYANA ROAD
-
SAN DIEGO,CA 92121
USA
ph: 858-558-0708
fax: -
investors@bioatla.com http://www.bioatla.com
 
 • General Corporate Information   
Officers
Jay M. Short - Chief Executive Officer and Director
Richard A. Waldron - Chief Financial Officer
Scott Smith - Director
Lawrence Steinman - Director
Mary Ann Gray - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09077B104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 58.42
Most Recent Split Date: (:1)
Beta: 0.91
Market Capitalization: $22.58 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.22 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 39.58%
vs. Previous Quarter: 9.38%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -373.47
12/31/24 - -238.62
ROA
06/30/25 - -
03/31/25 - -116.55
12/31/24 - -103.61
Current Ratio
06/30/25 - -
03/31/25 - 2.35
12/31/24 - 3.52
Quick Ratio
06/30/25 - -
03/31/25 - 2.35
12/31/24 - 3.52
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -562.51
12/31/24 - -634.33
Book Value
06/30/25 - -
03/31/25 - 0.01
12/31/24 - 0.25
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©